While there are a lot of NRF2 inducers, some of which are already approved for the treatment of multiple sclerosis (dimethyl fumarate) and Friedrich ataxia (omaveloxolone), there are no specific inhibitors of NRF2 thus far. This evidence concerns the gene NFE2L2 and multiple sclerosis.